SCYNEXIS to Present Data at ICAAC/ICC 2015 for Novel Antifungal Drug Candidate
JERSEY CITY, N.J., Sept. 10, 2015 (GLOBE NEWSWIRE) -- Drug discovery and development company SCYNEXIS, Inc. (Nasdaq:SCYX) today announced one podium and three poster presentations related to non-clinical studies of the Company's lead clinical drug candidate, SCY-078. The data will be presented at the upcoming Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC) and the International Congress of Chemotherapy (ICC) joint meeting, taking place September 17-21, 2015 in San Diego, California.
"With antifungal resistance on the rise, the dire need for new and novel therapies to treat patients remains acute," said Marco Taglietti, M.D., SCYNEXIS' Chief Executive Officer. "These data demonstrate the potential that SCY-078 may have in treating invasive and treatment-resistant fungal infections in humans and give us confidence to continue exploring SCY-078's broader clinical utility."
The details for the data presentations at ICAAC/ICC 2015 are as follows:
Podium presentation:
Overview of SCY-078 PK and penetration data supporting potential clinical utility in invasive fungal infections
Title: SCY-078 a Novel Glucan Synthesis Inhibitor: Oral and Intravenous Pharmacokinetics and Penetration in to Key Tissues Supports Potential Clinical Utility in Invasive Fungal Infections.
Presenter: S. Wring
Session Title: Early New Antimicrobial Agents
Date and time: Friday, September 18, 2015; 2:30 – 4:30 p.m. PT
Location: Ballroom 20D Upper Level
Posters:
Penetration of orally administered SCY-078 into murine pulmonary epithelial lining fluid exceeds plasma exposure.
Title: Penetration of SCY-078 into Pulmonary Epithelial Lining Fluid Suggests Potential Clinical Utility in Pulmonary Fungal Infections
Abstract #: A-468c
Presenter: S. Wring
Session Title: Clinical PK/PD
Date and Time: Saturday, September 19, 2015; 11:00 a.m. – 1:00 p.m.
Location: Exhibit Hall F
Extensive and prolonged murine kidney tissue distribution of intravenously administered SCY-078.
Title: Enhanced Distribution in Kidney Tissue Contributes to Lower Free Drug (f) AUC/MIC Pharmacodynamic Targets for the Oral Glucan Synthesis Inhibitor SCY-078 Compared to Echinocandins in Murine Models of Invasive Candidiasis
Abstract #: F-744
Presenter: S. Wring
Session Title: New Anti-fungal Agents
Date and Time: Saturday, September 19, 2015; 11:00 a.m. – 1:00 p.m. PT
Location: Exhibit Hall F
Pharmacokinetics of intravenous SCY-078 in dogs, rats and mice indicate high tissue distribution and plasma exposures exceeding estimated efficacy target for invasive candidiasis.
Title: Intravenous Single and Multiple Dose-Range Finding Pharmacokinetics of the Antifungal Triterpene SCY-078 in Mouse, Rat and Dog And Comparison to Efficacy Target in Murine Models of Invasive Candidiasis
Abstract #: F-745
Presenter: K. Borroto-Esoda
Session Title: New Anti-fungal Agents
Date and Time: Saturday, September 19, 2015; 11:00 a.m. – 1:00 p.m. PT
Location: Exhibit Hall F
About SCY-078
SCY-078 is an oral glucan synthase inhibitor in Phase II being developed for the treatment of invasive fungal infections including Candidemia and invasive Aspergillosis. SCY-078 is a semi-synthetic derivative of the natural product enfumafungin—a structurally distinct class of glucan synthase inhibitors. Glucan synthase inhibitors have been very effective in treating invasive fungal infections in a hospital setting, but are currently only available in intravenous formulations. The FDA designated SCY-078 as a Qualified Infectious Disease Product (QIDP) and has granted Fast Track status for oral use for the indications of invasive Candidiasis, including Candidemia, and invasive Aspergillosis. SCYNEXIS is developing both oral and intravenous formulations of SCY-078.
About SCYNEXIS, Inc.
SCYNEXIS is a pharmaceutical company committed to the discovery, development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. We are developing our lead product candidate, SCY-078, a novel antifungal in Phase 2, as an oral and intravenous (IV) drug for the treatment of serious and life-threatening invasive fungal infections in humans. For more information, visit www.scynexis.com.
Forward Looking Statement
Statements contained in this press release regarding matters that are not historical facts, including any future clinical trials, future performance of product candidates, the potential of SCY-078 to treat invasive fungal infections, the therapeutic and commercial potential of SCY-078, and the anticipated timing of clinical trials and therapeutic and commercial potential of SCY-078 are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results and the timing of these events, including regarding the further development of SCY-078, could differ materially from those anticipated in such forward-looking statements as a result of risks and uncertainties, which include, without limitation, risks related to: the success, cost and timing of any of SCYNEXIS's product development activities, including any current and future clinical trials of SCY-078; any delays or inability to obtain or maintain regulatory approval of product candidates in the United States or worldwide; the company's ability to obtain sufficient financing to complete development, regulatory approval and commercialization of its product candidates in the United States and worldwide; and the market potential for the company's product candidates. Risks are described more fully in SCYNEXIS'S filings with the Securities and Exchange Commission, including without limitation its most recent Quarterly Report on Form 10-Q and other documents subsequently filed with or furnished to the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. SCYNEXIS undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
CONTACT: Media Relations
Heather Savelle
MacDougall Biomedical Communications
Tel: 781-235-3060
hsavelle@macbiocom.com
Investor Relations
Susan Kim
Argot Partners
Tel: 212-203-4433
susan@argotpartners.com
Released September 10, 2015